EigenSample: A non-iterative technique for adding samples to small datasets

A narrative review for platelets and their RNAs in cancers: New concepts and clinical perspectives

Recent years have witnessed a growing body of evidence suggesting that platelets are involved in several stages of the metastatic process via direct or indirect interactions with cancer cells, contributing to the progression of neoplastic malignancies. Cancer cells can dynamically exchange components with platelets in and out of blood vessels, and directly phagocytose platelets to hijack their proteome, transcriptome, and secretome, or be remotely regulated by metabolites or microparticles released by platelets, resulting in phenotypic, genetic, and functional modifications. Moreover, platelet interactions with stromal and immune cells in the tumor microenvironment lead to alterations in their components, including the ribonucleic acid (RNA) profile, and complicate the impact of platelets on cancers. A deeper understanding of the roles of platelets and their RNAs in cancer will contribute to the development of anticancer strategies and the optimization of clinical management. Encouragingly, advances in high-throughput sequencing, bioinformatics data analysis, and machine learning have allowed scientists to explore the potential of platelet RNAs for cancer diagnosis, prognosis, and guiding treatment. However, the clinical application of this technique remains controversial and requires larger, multicenter studies with standardized protocols. Here, we integrate the latest evidence to provide a broader insight into the role of platelets in cancer progression and management, and propose standardized recommendations for the clinical utility of platelet RNAs to facilitate translation and benefit patients.

A CNN-LSTM network with multi-level feature extraction-based approach for automated detection of coronavirus from CT scan and X-ray images

Auto-detection of diseases has become a prime issue in medical sciences as population density is fast growing. An intelligent framework for disease detection helps physicians identify illnesses, give reliable and consistent results, and reduce death rates. Coronavirus (Covid-19) has recently been one of the most severe and acute diseases in the world. An automatic detection framework should therefore be introduced as the fastest diagnostic alternative to avoid Covid-19 spread. In this paper, an automatic Covid-19 identification in the CT scan and chest X-ray is obtained with the help of a combined deep learning and multi-level feature extraction methodology. In this method, the multi-level feature extraction approach comprises GIST, Scale Invariant Feature Transform (SIFT), and Convolutional Neural Network (CNN) extract features from CT scans and chest X-rays. The objective of multi-level feature extraction is to reduce the training complexity of CNN network, which significantly assists in accurate and robust Covid-19 identification. Finally, Long Short-Term Memory (LSTM) along the CNN network is used to detect the extracted Covid-19 features. The Kaggle SARS-CoV-2 CT scan dataset and the Italian SIRM Covid-19 CT scan and chest X-ray dataset were employed for testing purposes. Experimental outcomes show that proposed approach obtained 98.94% accuracy with the SARS-CoV-2 CT scan dataset and 83.03% accuracy with the SIRM Covid-19 CT scan and chest X-ray dataset. The proposed approach helps radiologists and practitioners to detect and treat Covid-19 cases effectively over the pandemic.

Molecular signature comprising 11 platelet-genes enables accurate blood-based diagnosis of NSCLC

BACKGROUND

Early diagnosis is crucial for effective medical management of cancer patients. Tissue biopsy has been widely used for cancer diagnosis, but its invasive nature limits its application, especially when repeated biopsies are needed. Over the past few years, genomic explorations have led to the discovery of various blood-based biomarkers. Tumor Educated Platelets (TEPs) have, of late, generated considerable interest due to their ability to infer tumor existence and subtype accurately. So far, a majority of the studies involving TEPs have offered marker-panels consisting of several hundreds of genes. Profiling large numbers of genes incur a significant cost, impeding its diagnostic adoption. As such, it is important to construct minimalistic molecular signatures comprising a small number of genes.

RESULTS

To address the aforesaid challenges, we analyzed publicly available TEP expression profiles and identified a panel of 11 platelet-genes that reliably discriminates between cancer and healthy samples. To validate its efficacy, we chose non-small cell lung cancer (NSCLC), the most prevalent type of lung malignancy. When applied to platelet-gene expression data from a published study, our machine learning model could accurately discriminate between non-metastatic NSCLC cases and healthy samples. We further experimentally validated the panel on an in-house cohort of metastatic NSCLC patients and healthy controls via real-time quantitative Polymerase Chain Reaction (RT-qPCR) (AUC = 0.97). Model performance was boosted significantly after artificial data-augmentation using the EigenSample method (AUC = 0.99). Lastly, we demonstrated the cancer-specificity of the proposed gene-panel by benchmarking it on platelet transcriptomes from patients with Myocardial Infarction (MI).

CONCLUSION

We demonstrated an end-to-end bioinformatic plus experimental workflow for identifying a minimal set of TEP associated marker-genes that are predictive of the existence of cancers. We also discussed a strategy for boosting the predictive model performance by artificial augmentation of gene expression data.